Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis

Sabrina Giacoppo, Federica Pollastro, Gianpaolo Grassi, Placido Bramanti, Emanuela Mazzon

Research output: Contribution to journalArticle

Abstract

This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35–55. After EAE onset, which occurs approximately 14 days after disease induction, mice were daily intraperitoneally treated with CBD (10 mg/kg mouse) and observed for clinical signs of EAE. At 28 days from EAE-induction, mice were euthanized and spinal cord tissues were sampled to perform immunohistochemical evaluations and western blot analysis. Our results showed a clear downregulation of the PI3K/Akt/mTOR pathway following EAE induction. CBD treatment was able to restore it, increasing significantly the phosphorylation of PI3K, Akt and mTOR. Also, an increased level of BNDF in CBD-treated mice seems to be involved in the activation of PI3K/Akt/mTOR pathway. In addition, our data demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-γ and IL-17 together with an up-regulation of PPARγ. Finally, CBD was found to promote neuronal survival by inhibiting JNK and p38 MAP kinases. These results provide an interesting discovery about the regulation of the PI3K/Akt/mTOR pathway by cannabidiol administration, that could be a new potential therapeutic target for MS management.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalFitoterapia
Volume116
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Cannabidiol
Phosphatidylinositol 3-Kinases
Multiple Sclerosis
Autoimmune Experimental Encephalomyelitis
Therapeutics
Peroxisome Proliferator-Activated Receptors
Interleukin-17
Cannabinoids
p38 Mitogen-Activated Protein Kinases
Myelin Sheath
Inbred C57BL Mouse
Immunization
Spinal Cord
Glycoproteins
Up-Regulation
Down-Regulation
Western Blotting
Phosphorylation
Cytokines
Peptides

Keywords

  • BDNF
  • Cannabidiol
  • Inflammation
  • Multiple sclerosis
  • Neuronal survival
  • PI3K/Akt/mTOR pathway

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. / Giacoppo, Sabrina; Pollastro, Federica; Grassi, Gianpaolo; Bramanti, Placido; Mazzon, Emanuela.

In: Fitoterapia, Vol. 116, 01.01.2017, p. 77-84.

Research output: Contribution to journalArticle

@article{8f942e60e2404972b458f24403472e57,
title = "Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis",
abstract = "This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35–55. After EAE onset, which occurs approximately 14 days after disease induction, mice were daily intraperitoneally treated with CBD (10 mg/kg mouse) and observed for clinical signs of EAE. At 28 days from EAE-induction, mice were euthanized and spinal cord tissues were sampled to perform immunohistochemical evaluations and western blot analysis. Our results showed a clear downregulation of the PI3K/Akt/mTOR pathway following EAE induction. CBD treatment was able to restore it, increasing significantly the phosphorylation of PI3K, Akt and mTOR. Also, an increased level of BNDF in CBD-treated mice seems to be involved in the activation of PI3K/Akt/mTOR pathway. In addition, our data demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-γ and IL-17 together with an up-regulation of PPARγ. Finally, CBD was found to promote neuronal survival by inhibiting JNK and p38 MAP kinases. These results provide an interesting discovery about the regulation of the PI3K/Akt/mTOR pathway by cannabidiol administration, that could be a new potential therapeutic target for MS management.",
keywords = "BDNF, Cannabidiol, Inflammation, Multiple sclerosis, Neuronal survival, PI3K/Akt/mTOR pathway",
author = "Sabrina Giacoppo and Federica Pollastro and Gianpaolo Grassi and Placido Bramanti and Emanuela Mazzon",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.fitote.2016.11.010",
language = "English",
volume = "116",
pages = "77--84",
journal = "Fitoterapia",
issn = "0367-326X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis

AU - Giacoppo, Sabrina

AU - Pollastro, Federica

AU - Grassi, Gianpaolo

AU - Bramanti, Placido

AU - Mazzon, Emanuela

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35–55. After EAE onset, which occurs approximately 14 days after disease induction, mice were daily intraperitoneally treated with CBD (10 mg/kg mouse) and observed for clinical signs of EAE. At 28 days from EAE-induction, mice were euthanized and spinal cord tissues were sampled to perform immunohistochemical evaluations and western blot analysis. Our results showed a clear downregulation of the PI3K/Akt/mTOR pathway following EAE induction. CBD treatment was able to restore it, increasing significantly the phosphorylation of PI3K, Akt and mTOR. Also, an increased level of BNDF in CBD-treated mice seems to be involved in the activation of PI3K/Akt/mTOR pathway. In addition, our data demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-γ and IL-17 together with an up-regulation of PPARγ. Finally, CBD was found to promote neuronal survival by inhibiting JNK and p38 MAP kinases. These results provide an interesting discovery about the regulation of the PI3K/Akt/mTOR pathway by cannabidiol administration, that could be a new potential therapeutic target for MS management.

AB - This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35–55. After EAE onset, which occurs approximately 14 days after disease induction, mice were daily intraperitoneally treated with CBD (10 mg/kg mouse) and observed for clinical signs of EAE. At 28 days from EAE-induction, mice were euthanized and spinal cord tissues were sampled to perform immunohistochemical evaluations and western blot analysis. Our results showed a clear downregulation of the PI3K/Akt/mTOR pathway following EAE induction. CBD treatment was able to restore it, increasing significantly the phosphorylation of PI3K, Akt and mTOR. Also, an increased level of BNDF in CBD-treated mice seems to be involved in the activation of PI3K/Akt/mTOR pathway. In addition, our data demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-γ and IL-17 together with an up-regulation of PPARγ. Finally, CBD was found to promote neuronal survival by inhibiting JNK and p38 MAP kinases. These results provide an interesting discovery about the regulation of the PI3K/Akt/mTOR pathway by cannabidiol administration, that could be a new potential therapeutic target for MS management.

KW - BDNF

KW - Cannabidiol

KW - Inflammation

KW - Multiple sclerosis

KW - Neuronal survival

KW - PI3K/Akt/mTOR pathway

UR - http://www.scopus.com/inward/record.url?scp=84999252436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999252436&partnerID=8YFLogxK

U2 - 10.1016/j.fitote.2016.11.010

DO - 10.1016/j.fitote.2016.11.010

M3 - Article

AN - SCOPUS:84999252436

VL - 116

SP - 77

EP - 84

JO - Fitoterapia

JF - Fitoterapia

SN - 0367-326X

ER -